Company profile: BostonGene
1.1 - Company Overview
Company description
- Provider of AI-powered molecular and immune profiling and a cloud-based platform for personalized cancer therapy analysis; multiplex immunofluorescence (MxIF) pipeline analyzing tissue architecture and cell interactions, detecting up to 40 protein markers; bioinformatics services using multi-omics databases and proprietary software; biopharma solutions and target analysis to evaluate drug candidates in a certified environment.
Products and services
- Molecular and Immune Profiling: AI-based profiling examines molecular and immune characteristics to pinpoint effective cancer treatments, delivering targeted therapy options derived from combined molecular and immune analyses
- Biopharma Solutions: Cloud-based platform integrates molecular and immune profiling to perform personalized therapy analysis, enabling combined assessments of tumor, microenvironment, and host immunity
- Multiplex Immunofluorescence (MxIF) Pipeline: Single-slide workflow analyzes tissue architecture and cell interactions, detecting up to 40 protein markers from one slide for tissue characterization
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to BostonGene
Bluebird Bio
HQ: United States
Website
- Description: Provider of gene therapies for severe genetic and rare diseases, developing gene addition treatments that modify patient cells to address underlying genetic causes using lentiviral vectors. Products include LentiGlobin for sickle cell disease, Lenti-D for cerebral adrenoleukodystrophy, and Zynteglo for beta-thalassemia.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Bluebird Bio company profile →
Select Immunogenomics
HQ: United States
Website
- Description: Provider of data analysis, predictive modeling, and reporting in support of genomic studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Select Immunogenomics company profile →
Horizon Discovery
HQ: United Kingdom
Website
- Description: Provider of gene editing and gene modulation platforms and services, including the Pin-point Base Editing Platform for precise base changes, Dharmacon siRNA, shRNA, and CRISPR reagents, drug discovery screening services, pre-engineered cell lines, and Mimix cell line-derived molecular reference standards for research and clinical applications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Horizon Discovery company profile →
GreenLight Biosciences
HQ: United States
Website
- Description: Provider of RNA-based solutions for agriculture and human health, offering a proprietary platform to produce RNA at scale cost-effectively and products targeting pests and diseases without harming beneficial insects, including Varroa mite control for honeybees and Calantha, an EPA-approved RNA product for Colorado Potato Beetle control.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GreenLight Biosciences company profile →
Claritas Genomics
HQ: United States
Website
- Description: Provider of genomics solutions, established as a new venture through a partnership between Boston Children's Hospital and Life Technologies Corp.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Claritas Genomics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for BostonGene
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to BostonGene
2.2 - Growth funds investing in similar companies to BostonGene
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for BostonGene
4.2 - Public trading comparable groups for BostonGene
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →